In a second keynote address during the same ACC conference Dr. Prediman K. Shah, Director of the Division of Cardiology and the Atherosclerosis Research Center at Cedars-Sinai Medical Center highlighted the advances of RVX-208 during his presentation titled "Novel strategies to increase HDL". During his presentation, Dr. Shah reviewed the unique features of RVX-208's novel mechanism of action and properties by which ApoA-I and functional HDL are increased.
Resverlogix continues to expand its scientific leadership through participation in key scientific conferences including presenting data on April 30, 2009 during the AHA Arteriosclerosis, Thrombosis and Vascular Biology Annual conference. On June 18, 2009 Resverlogix will be participating in a workshop that examines therapies which enhance reverse cholesterol transport during the XV International Symposium on Atherosclerosis hosted by the International Atherosclerosis Society.
Resverlogix granted 1,430,000 stock options to new employees, officers and directors and existing employees whose options expired during an extensive blackout period. During the past fiscal year 1,483,900 option grants expired, of which all director and officers expired options were priced below current market value. Given the expiry of these options, the new grant has a neutral effect on the capital structure of the company. The stock options plan provides for the issuance of up to a maximum of 10% of the issued and outstanding common shares. Subsequent to this option grant, the total options outstanding is equal to 6.9% of the issued and outstanding common shares and was 4.7% prior to the recent financing.
|SOURCE Resverlogix Corp.|
Copyright©2009 PR Newswire.
All rights reserved